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Trial management: we need a cadre of
high-class triallists to deliver the answers
that patients need
Danielle Beaumont, Monica Arribas, Lauren Frimley, Eni Balogun, Ian Roberts and Haleema Shakur-Still*
Abstract
Expert trial managers with the training and experience to overcome operational challenges are often the difference
between the success and failure of a clinical trial. Considerable importance is given to the beginning and the end
of the clinical trial process, with those responsible for writing a protocol, obtaining funding and analysing the data
all being rewarded when the results are published. Yet, trial managers are often overlooked in terms of recognition,
value and status. This article highlights some of the key barriers to achieving this and makes suggestions on how
they can be addressed within clinical trials units registered with the UK Clinical Research Collaboration.
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Background
Large randomised trials are used to identify modest but
worthwhile treatment effects and so practical ways to
increase the size of trials are needed [1]. Recruiting large
numbers of participants often requires the trial to be
multicentre and international, which brings a range of
operational challenges, including the need to meet regu-
latory and ethical requirements, supply the trial mate-
rials, overcome language barriers and other challenges
arising from the need to scale up recruitment. Expert
trial managers with the training and experience to over-
come these challenges are often the difference between
success and failure.
In 2008, 48,295 studies were registered in Clinical-
Trials.gov, and by August 2018, this had increased to
282,848 [2]. The number of studies supported by the
National Institute of Health Research (NIHR) increased
from 1787 in the year 2016 to 2070 by 2018. [3, 4], and
funding for research from the Medical Research Council
has increased from £233 million to £337 million in 10
years [5]. With the number of trials increasing, many
more expert trial managers are needed, especially to en-
sure that large trials are conducted properly.
Considerable importance is given to the beginning and
the end of the clinical trial process, with those respon-
sible for writing a protocol, obtaining funding and ana-
lysing the data all being rewarded when the results are
published. In the recently published WOMAN trial [6]
for example, the project management plan allocated 9
months for protocol development and 6months for
preparation of the manuscript. However, what dictates a
successful trial is the action taken between when the
proposal is funded and when it is analysed, i.e. the con-
duct of the trial, which for the WOMAN trial amounted
to 6.5 years. Trial managers, utilising their unique skillset
and expertise, usually oversee the conduct of a trial. Yet,
trial managers are usually overlooked in terms of recog-
nition, value and status. A recent correspondence in The
Lancet called for a cadre of high-class clinical triallists
(expert trial managers) who can deliver successful trials
to maximise patient benefit [7]. Recognition of the work
of trial managers and continued progression and devel-
opment within trial management are essential for
achieving this. The aim of this paper is to highlight some
of the key barriers to achieving this and to make sugges-
tions on how they can be addressed. In particular, we
will draw on our experience of working on academic
trials within a clinical trials unit (CTU) registered with
the UK Clinical Research Collaboration.
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The role of a trial manager in a large-scale trial
In response to the call from Peto and Baigent [1], we
have conducted several successful large-scale rando-
mised trials to answer important questions for patients.
We recruited over 50,000 patients over 16 years to the
CRASH-1 [8], CRASH-2 [9] and WOMAN trials [6]. All
these trials recruited on time, to target and within
budget and importantly, all these trials have changed
clinical practice with international treatment guidelines
updated to incorporate the trial results. Furthermore,
this work continues with the CRASH-3 [10] and HALT-
IT [11] trials, which are due to end recruitment in 2019,
by which time the total number of patients recruited will
be about 75,000 (Table 1).
Without skilful management, which is the domain of
the expert trial manager, these trials would not be the
big, multicentre, international, successful trials they are.
Project management expertise alone is not enough to
deliver multimillion-pound trials. A sound understand-
ing of trial design and methodology, research operations
and logistics, and the unique research context in each
country taking part in the trial are also needed.
Patient recruitment, which is primarily the responsibil-
ity of the trial manager, is vital to the success of any trial.
The NIHR Human Tissue Authority recommends that
all primary research projects appoint a dedicated pro-
ject/trial manager. The NIHR-funded STEPS study,
which aimed to identify factors associated with good and
poor recruitment to multicentre trials, showed that trials
that recruited successfully had a dedicated trial manager
[12]. The published manuscript of the WOMAN trial
simply states that ‘between March 2010, and April 2016,
20 060 women were enrolled’. This statement gives no
insight into the intricacies of this responsibility and con-
ceals the reality of the day-to-day challenges faced by
trial managers in achieving the steady increase over time
that is shown in the cumulative recruitment graph for
the trial (Fig. 1). Figure 2 shows the constant fluctuation
in monthly recruitment into the trial during its lifetime.
To keep the trial on track required persistent effort in
dealing with various threats to recruitment in participat-
ing hospitals or whole countries, from political upheaval
and natural disasters, to clinical trial supplies being
blocked by customs authorities. Dealing with such
threats whilst ensuring that the trial remained on track
required critical thinking and creative solutions.
Developing and managing the patient recruitment
strategy is only one part of what a trial manager must do
to deliver a multicentre international trial successfully,
such as the WOMAN trial. In that trial, the trial man-
ager also had to: (1) develop trial procedures applicable
to both resource-rich and resource-poor settings, (2)
create, train and motivate a team (spread across the co-
ordinating centre, national centres and sites), (3) ensure
follow-ups were completed, (4) comply with all legal and
ethical requirements across 21 countries, (5) arrange the
manufacture and shipment of trial drugs, (6) report to
all oversight committees and funders, (7) monitor trial
activities, (8) analyse and interpret data on recruitment,
which includes centrally monitoring recruitment statis-
tics and the quality of the data, (9) ensure participants’
human rights are protected in line with good clinical
practice guidelines and (10) ensure the budget was man-
aged properly. It is clear a trial manager’s role is intellec-
tual, unique, diverse and complex.
Funders need to value the skills of trial managers
In general, trial managers are handed a trial for which
the funding decisions have already been made. They are
then asked to deliver a workable protocol and produce
valid data ready for analysis and publication. However,
funders should require that the team of academics
submitting a proposal have involved a trial manager.
The application should name the trial manager and de-
scribe their specific expertise, experience and contribu-
tion to the proposal. This will ensure that the best
application is submitted with appropriate input from all
experts, for example, those with clinical, statistical and
trial management skills.
Once a proposal is submitted, funders rarely involve
expert trial managers at the board review stage. After an
online search of their websites on 30 May 2018, we
reviewed the composition of the funding boards of three
main UK funders: the Medical Research Council, NIHR
and the Wellcome Trust. Across the three funding
boards, we identified 77 committees, panels and expert
review groups with 1134 members listed. Some members
sat on more than one board. Our search showed that
none of the funding boards had a member with a job
title of ‘trial manager’ or ‘trial management expert’.
Funding board members are usually selected for their
expertise, experience and specialist skills. Trial managers
Table 1 Overview of the CRASH-1, CRASH-2, WOMAN, CRASH-3 and HALT-IT trials
CRASH-1 CRASH-2 WOMAN CRASH-3 HALT-IT
Dates (recruitment) 1999–2004 2005–2010 2010–2016 2012–2019 2013–2019
Patients 10,008 20,211 20,000 13,000 12,000
Sites 239 274 193 175 161
Countries 49 40 21 29 14
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with their unique experience in conducting trials are
generally excluded from this early process.
Another key aspect in which funders can have an impact
is investing in the development of the body of knowledge
needed to manage trials, which could prevent many trials
from failing. The call for more evidence to support deci-
sions on the design, conduct and reporting of clinical trials
has been ongoing for over 30 years [13, 14]. The recent
Trial Forge initiative will develop the science of trial
methodology. It aims to provide the evidence needed to im-
prove trial efficacy and for conducting studies within a trial
(SWATs). It is a small start in developing methodology
closely aligned to a trial manager’s skillset [15]. This initia-
tive is evaluating and exploring alternative ways of deliver-
ing and organising trials. It recommends that SWATs
should be embedded in all funded trials. Moreover, a recent
Fig. 1 Cumulative recruitment for the WOMAN trial
Fig. 2 Monthly recruitment for the WOMAN trial
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study highlighted concerns from CTUs regarding applica-
tions for SWATs. Examples included the main funding
application being rejected due to the additional costs of a
SWAT and insufficient time being allocated to develop the
SWAT due to tight submission timelines [16]. Funders
commented that there is a misconception surrounding
what money is available for. However, funders should real-
ise that the SWAT component of a trial can be vital and
they should fund SWATs adequately. They should ensure
there are sufficient resources to cover this additional im-
portant work. Funders could also allow for a SWAT to be
embedded later or actively request that a SWAT is included
in funding applications.
The role of journals in recognising the importance of trial
management
The structure of a traditional scientific manuscript
favours the scientific and statistical aspects. Neither
successful nor problematic trial management aspects are
expected to be reported in a clinical trial publication.
Some trials are delivered successfully but many more
encounter difficulties in recruitment, consent, adherence
to the intervention, follow-ups, regulatory and ethical
issues, and quality management. The opportunity to
learn from clinical trials is enormous. The inclusion of
trial management methodology as part of a clinical trial
publication will ensure that the knowledge acquired
during the conduct of each trial is not lost and can be
applied in future trials and subsequently used to develop
trial methodology further. Editors of medical journals
need to consider the importance of how good research
is actually carried out and should require that trial man-
agement methods are included in descriptions of trials
in high-quality journals. Whilst more papers are describ-
ing trial management [17–19] as good practice, doing so
is not mandatory. Transparency in the publication of
trial management methods is not expected, unlike the
publication of basic research.
Authorship is important in recognising and attributing
contribution in a trial manuscript. During the peer
review, reviewers and journal editors should ensure that
there is an appropriate acknowledgement of the trial
manager and require that the trial manager is a named
author. In addition, a line acknowledging the trial man-
agement team should be permitted.
Gender inequality and the role of the trial manager
In a clinical trial, the chief investigator is most likely to
be a he as women remain underrepresented in leader-
ship roles [20, 21] and as funding recipients [22, 23]. In
contrast, trial managers are ‘she, seldom he’ [24]. On 30
May 2018, we reviewed the websites of 46 CTUs regis-
tered with the UK Clinical Research Collaboration. Staff
lists were available for 37 of them. Based on title, name
and photographs, we identified that approximately 83%
of trial managers were female. This leads to a hierarch-
ical structure and a power imbalance between trial man-
agers and chief investigators. Because the predominantly
female role of trial management is situated within a stark
sexual division of labour alongside the predominantly
male role of chief investigator, gender may account for a
significant part of the inequalities. Whilst we acknow-
ledge gender imbalance and inequalities are not specific
to trial managers but widespread across different indus-
tries, to ensure continued progression and development
of talented trial managers, both male and female, and to
develop the leaders needed, it is important to address
the reasons for this. For example, is the gender imbal-
ance of trial managers attributed to the perceived skillset
for the role? What can be done to ensure that there are
more females in positions of leadership within trial man-
agement? Women remain underrepresented as recogni-
tion award recipients [25–28].
It is important to examine this gender imbalance and
to determine the impact that such an imbalance might
have on the continued progression and development of
trial managers. For instance, is there less focus on creat-
ing pathways that would facilitate interested trial man-
agers to progress to chief investigator roles within CTUs
because of a general perception that women are stronger
and more useful in support roles?
Trial managers themselves might hold some responsi-
bility for the lack of recognition of their contribution in
clinical trials. It is known that women talk down their
achievements and undervalue themselves when working
in a successful group alongside men [29].
Trials are delivered through collaborative working.
A collaboration is an interdependence that requires
the complementarity of roles [30]. The notion that the
chief investigator’s role and the trial manager’s role
complement each other is essential in delivering clin-
ical trials successfully.
Career structure and professional recognition for trial
managers
Trial managers are predominantly accidental triallists,
having learnt their skills from their peers through on the
job training supported with in-house training. However,
trial managers at every level should develop the skills
needed to deliver high-quality clinical trials confidently
and competently. It is crucial that training opportunities
and continued professional development are available
and experiences are shared to develop the expert trial
managers of the future.
The NIHR Task, Knowledge and Competency Frame-
work for trial managers identifies three competency
levels: novice, experienced and senior [31]. Trial man-
agers working within CTUs are provided with support
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and a structure around these roles to achieve progres-
sion. Yet, whilst the framework is a useful tool to pro-
gress individuals through from early to perhaps mid-
career, as it currently stands, expert trial managers hit a
glass ceiling. The framework does not outline further
opportunities for progression in which CTUs can offer
continued support, nor does it recognise that trial man-
agers can become leaders in their field.
Appropriate career structures are needed for trial
managers to develop into leaders, achieve career success
and build the knowledge base to support the profession.
One approach used by the London School of Hygiene &
Tropical Medicine’s CTU is to develop the expertise of
trial managers through an academic pathway, which
allows trial managers to complete appropriate post-
graduate education and to develop the methodological
skills needed to build the body of knowledge and
evidence base for efficient and expert trial management.
However, it is recognised that not all trial managers
want an academic career and alternative pathways are
also needed with a focus on the management and leader-
ship skills required to deliver a trial successfully. Prac-
tical support should also be provided within institutions
for expert trial managers to develop their own funding
proposals for their own research (for instance, develop-
ing SWATs), which would be aimed at developing the
overall body of knowledge and allowing them to develop
as leaders.
The last few years have seen some growth in training
and educational opportunities for trial managers. The
UK Trial Managers Network has developed workshops
to support trial managers’ core work [32]. Several MSc
programmes covering clinical trials [33–36] and short
courses on clinical trial management [37–40] are now
available. However, education programmes and training
can be expensive. Research funders and employing insti-
tutions need to invest in the training of trial managers to
ensure the successful delivery of clinical trials. NIHR
leadership programmes are available for early career
researchers [41]. Such leadership programmes are also
needed to develop expert trial managers.
We propose that one way to formally address training,
education and career structure needs and to recognise the
expertise of trial managers is professional accreditation of
trial managers. Steps have already been made by the UK
Trial Managers Network to develop a professional ac-
creditation scheme for trial managers. The network is
attempting to formalise this process and its continuing
work must be appropriately supported. Trial managers
need a formal body to represent their work, which the UK
Trial Managers Network has provided to date. However,
what is needed to support professionalisation is a body
that also maintains oversight of the knowledge, skills, con-
duct and practice of trial management.
Conclusion
Trial managers are vital to the success of clinical trials.
The contribution of trial managers needs to be recog-
nised, rewarded and valued by funders, journals, aca-
demic institutions and their peers. This will signal their
status, their confidence, the trust placed in them and
their professional autonomy. Academic institutions host-
ing CTUs need to provide training and development
opportunities that will facilitate progression beyond trial
management to chief investigator or a relevant academic
role if desired. There should be appropriate career path-
ways for trial managers wanting to remain within the
field as experts. The professionalisation of trial manage-
ment should be enhanced through education and train-
ing. These measures will go some way in developing a
cadre of high-class triallists who will be able to ensure
the success of future clinical trials that deliver the an-
swers that patients need.
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